Published On Premiered Feb 9, 2024
Jeffrey B. Simon, trial attorney and author of the book 'Last Rights: The Fight to Save the Seventh Amendment.' Discusses the $1.8 billion settlement from Johnson & Johnson related to opioids, and the role of Purdue Pharma and the Sackler family in the opioid epidemic. Diving into the larger issue of the dismantling of the civil justice system and the impact of tort reform. The conversation concludes with personal insights from Simon on advice, his first job, and personal views on life.
Takeaways
- The $1.8 billion settlement from Johnson & Johnson highlights the harm caused by the overprescription and misleading promotion of opioids.
- Purdue Pharma, owned by the Sackler family, is accused of starting the prescription opioid epidemic by overpromoting OxyContin as less addictive and more effective than it actually is.
- The bankruptcy process and the settlement with Purdue Pharma raise questions about the accountability of the Sackler family and the use of bankruptcy protections.
- The civil justice system has been undermined by legislative initiatives and tort reform, which favor corporations over consumer rights and public safety.
Chapters
00:00 Introduction and Background
01:25 The Fight to Save the Seventh Amendment
03:02 Opioids and the $1.8 Billion Settlement
09:06 Purdue Pharma and the Sackler Family
14:18 Mixed Feelings on the Settlement
18:10 The Dismantling of the Civil Justice System
19:05 Tort Reform and Political Divide
23:43 Rapid Fire Questions
Check out www.razreport.com for more episodes!
Follow us Online!
📸Instagram: www.instagram.com/benzinga
👍Facebook: www.facebook.com/Benzinga
📱TikTok: www.tiktok.com/@benzinga
🐤Twitter: twitter.com/Benzinga
Disclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.
#Benzinga #lawyer #bigpharma #rights #drug #crisis